[38; 39], several kinds of molecules; endonexin II [40], asialoglycoprotein receptor (ASGPR) [41; 42], lipoprotein lipase (LPL) [43], gp120 and gp180 (carboxypeptidase D) [17; 44] and so on were reported for HBV receptors, including those for DHBV. None of them, however, has been utilized for establishing an *in vitro* HBV infection system as an HBV receptor molecule. And most recently, NTCP (sodium-taurocholate co-transporting protein) has been nominated as a plausible HBV receptor molecule, which has been under evaluation [45; 46; 47].

On the other hand, the ligand, i.e., HBV membrane proteins have been characterized as well. There are three kinds of HBV membrane proteins; large S (LS), middle S (MS) and small S (SS) and seems to be no doubt that preS1 region in the N-terminal end of LS has a key role for receptor binding [48]. Especially, a well-conserved region around preS1 9-23 amino acids (aa) might be critically important and might function as a fusogenic peptide, since antibodies against preS1 (2-48 aa) could neutralize HBV infection but not preS1 (1-21 aa) in PTH system [49; 50; 51]. And also, experiments using hepatitis delta virus (HDV) provided us with similar important information on the HBV entry [52; 53; 54].

Nevertheless, we have yet obtained an easy and convenient *in vitro* cell culture system for HBV infection. Thus, identifying an HBV receptor seems to be very hard, because it has not been achieved for a half century since HBV was found. We do not understand why classical methods such as a phage screening system expressing human liver cDNA library and so on do not work well and therefore, we may need to design a new revolutionary assay system.

We here would like to propose a new biological assay using HBV pseudotype particles (HBVpp) in which retroviral core particles were enveloped by HBV membrane proteins. Successful production of HBVpp would allow us to test HBVpp infectivity to cell culture systems introduced some cDNA library from human hepatocytes and/or differentiated HepaRG cells. In this report, we tested whether such HBVpp could be generated. The immunoprecipitation with anti-HBs antibodies followed by RT-PCR and the physicochemical study using ultracentrifugation followed by RT-PCR revealed that murine leukemia virus based core/capsid, which contained recombinant retroviral genomes with *EGFP* and Hyg^R, were enveloped by HBV membrane particles. Thus, HBVpp should be generated and next question would be whether this HBVpp really could infect well-differentiated hepatocytes at suitable condition. It could be a weak point that the HBVpp was based on murine leukemia virus, which demanded cell growth for efficient viral genome integration into the host genome, compared to the same kind system based on a lentivirus. The HBV receptor could be a complex consisted of several molecules. In such a case, it should be very difficult to clone the HBV receptor by cDNA library introduction to ordinary cells, since two hits or more might be required. Nevertheless, it could possibly work if a cDNA encoding an HBV receptor or a gene affecting HBV attachment and entry from a human liver source was tested for HBV infectivity in various hepatoma cell culture systems_and thus this HBVpp will be a powerful tool for separation and identification of an HBV receptor with infectivity as a polestar.

References

[1] Blumberg, B.S., Alter, H.J., and Visnich, S., A "New" Antigen in Leukemia Sera. JAMA 191 (1965) 541-546.

[2] Seeger, C., Zoulim, F., and Mason, W.S., Hepadnaviruses, Lippincott Williams and Wilkins, Philadelphia, 2007.

[3] Funk, A., Mhamdi, M., Will, H., and Sirma, H., Avian hepatitis B viruses: molecular and cellular biology, phylogenesis, and host tropism. World J Gastroenterol 13 (2007) 91-103.

[4] Sureau, C., Eichberg, J.W., Hubbard, G.B., Romet-Lemonne, J.L., and Essex, M., A molecularly cloned hepatitis B virus produced in vitro is infectious in a chimpanzee. J Virol 62 (1988) 3064-3067.

[5] Bchini, R., Capel, F., Dauguet, C., Dubanchet, S., and Petit, M.A., In vitro infection of human hepatoma (HepG2) cells with hepatitis B virus. J Virol 64 (1990) 3025-3032.

[6] Paran, N., Geiger, B., and Shaul, Y., HBV infection of cell culture:

evidence for multivalent and cooperative attachment. EMBO J 20 (2001) 4443-4453.

[7] Gripon, P., Rumin, S., Urban, S., Le Seyec, J., Glaise, D., Cannie, I., Guyomard, C., Lucas, J., Trepo, C., and Guguen-Guillouzo, C., Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 99 (2002) 15655-15660.

[8] Marion, M.J., Hantz, O., and Durantel, D., The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies. Methods Mol Biol 640 (2010) 261-272.

[9] Bissig, K.D., Wieland, S.F., Tran, P., Isogawa, M., Le, T.T., Chisari, F.V., and Verma, I.M., Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 120 (2010) 924-930.

[10] Meuleman, P., and Leroux-Roels, G., The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and

HCV. Antiviral Res 80 (2008) 231-238.

[11] Dandri, M., Burda, M.R., Torok, E., Pollok, J.M., Iwanska, A., Sommer, G., Rogiers, X., Rogler, C.E., Gupta, S., Will, H., Greten, H., and Petersen, J., Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 33 (2001) 981-988.

[12] Llovet, J.M., Burroughs, A., and Bruix, J., Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917.

[13] Kremsdorf, D., Soussan, P., Paterlini-Brechot, P., and Brechot, C., Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 25 (2006) 3823-3833.

[14] Lupberger, J., and Hildt, E., Hepatitis B virus-induced oncogenesis. World J Gastroenterol 13 (2007) 74-81.

[15] Baumert, T.F., Thimme, R., and von Weizsacker, F., Pathogenesis of hepatitis B virus infection. World J Gastroenterol 13 (2007) 82-90.

[16] Li, J.S., Tong, S.P., and Wands, J.R., Characterization of a 120-Kilodalton pre-S-binding protein as a candidate duck hepatitis B

virus receptor. J Virol 70 (1996) 6029-6035.

[17] Kuroki, K., Cheung, R., Marion, P.L., and Ganem, D., A cell surface protein that binds avian hepatitis B virus particles. J Virol 68 (1994) 2091-2096.

[18] Breiner, K.M., Urban, S., and Schaller, H., Carboxypeptidase D (gp180), a Golgi-resident protein, functions in the attachment and entry of avian hepatitis B viruses. J Virol 72 (1998) 8098-8104.

[19] Cerec, V., Glaise, D., Garnier, D., Morosan, S., Turlin, B., Drenou, B., Gripon, P., Kremsdorf, D., Guguen-Guillouzo, C., and Corlu, A., Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45 (2007) 957-967.

[20] Parent, R., Marion, M.J., Furio, L., Trepo, C., and Petit, M.A., Origin and characterization of a human bipotent liver progenitor cell line. Gastroenterology 126 (2004) 1147-1156.

[21] Dropulic, B., Lentiviral vectors: their molecular design, safety, and use

in laboratory and preclinical research. Hum Gene Ther 22 (2011) 649-657.

[22] Sung, V.M., and Lai, M.M., Murine retroviral pseudotype virus containing hepatitis B virus large and small surface antigens confers specific tropism for primary human hepatocytes: a potential liver-specific targeting system. J Virol 76 (2002) 912-917.

[23] Saha, M.N., Tanaka, A., Jinno-Oue, A., Shimizu, N., Tamura, K., Shinagawa, M., Chiba, J., and Hoshino, H., Formation of vesicular stomatitis virus pseudotypes bearing surface proteins of hepatitis B virus. J Virol 79 (2005) 12566-12574.

[24] Chai, N., Chang, H.E., Nicolas, E., Gudima, S., Chang, J., and Taylor, J., Assembly of hepatitis B virus envelope proteins onto a lentivirus pseudotype that infects primary human hepatocytes. J Virol 81 (2007) 10897-10904.

[25] Evans, M.J., von Hahn, T., Tscherne, D.M., Syder, A.J., Panis, M., Wolk, B., Hatziioannou, T., McKeating, J.A., Bieniasz, P.D., and Rice, C.M.,

Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446 (2007) 801-805.

[26] Glebe, D., and Urban, S., Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol 13 (2007) 22-38.

[27] Ueda, K., Tsurimoto, T., and Matsubara, K., Three envelope proteins of hepatitis B virus: large S, middle S, and major S proteins needed for the formation of Dane particles. J Virol 65 (1991) 3521-3529.

[28] Bruss, V., and Ganem, D., The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci U S A 88 (1991) 1059-1063.

[29] Chairez, R., Hollinger, F.B., Melnick, J.L., and Dreesman, G.R., Biophysical properties of purified morphologic forms of hepatitis B antigen. Intervirology 3 (1974) 129-140.

[30] Lacombe, K., Boyd, A., Gozlan, J., Lavocat, F., Girard, P.M., and Zoulim, F., Drug-resistant and immune-escape HBV mutants in HIV-infected hosts. Antivir Ther 15 (2010) 493-497.

[31] Sheldon, J., and Soriano, V., Hepatitis B virus escape mutants induced

by antiviral therapy. J Antimicrob Chemother 61 (2008) 766-768.

[32] Zoulim, F., Antiviral therapy of chronic hepatitis B. Antiviral Res 71 (2006) 206-215.

[33] Locarnini, S.A., and Yuen, L., Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther 15 (2010) 451-461.

[34] Gripon, P., Diot, C., and Guguen-Guillouzo, C., Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration. Virology 192 (1993) 534-540.

[35] Kock, J., Nassal, M., MacNelly, S., Baumert, T.F., Blum, H.E., and von Weizsacker, F., Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J Virol 75 (2001) 5084-5089.

[36] Lanford, R.E., Chavez, D., Brasky, K.M., Burns, R.B., 3rd, and Rico-Hesse, R., Isolation of a hepadnavirus from the woolly monkey, a New World primate. Proc Natl Acad Sci U S A 95 (1998) 5757-5761.

[37] Hantz, O., Parent, R., Durantel, D., Gripon, P., Guguen-Guillouzo, C., and Zoulim, F., Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. J Gen Virol 90 (2009) 127-135.

[38] Yu, M.W., Finlayson, J.S., and Shih, J.W., Interaction between various polymerized human albumins and hepatitis B surface antigen. J Virol 55 (1985) 736-743.

[39] Pontisso, P., Petit, M.A., Bankowski, M.J., and Peeples, M.E., Human liver plasma membranes contain receptors for the hepatitis B virus pre-S1 region and, via polymerized human serum albumin, for the pre-S2 region. J Virol 63 (1989) 1981-1988.

[40] Hertogs, K., Leenders, W.P., Depla, E., De Bruin, W.C., Meheus, L., Raymackers, J., Moshage, H., and Yap, S.H., Endonexin II, present on human liver plasma membranes, is a specific binding protein of small hepatitis B virus (HBV) envelope protein. Virology 197 (1993) 549-557.

[41] Treichel, U., Meyer zum Buschenfelde, K.H., Stockert, R.J., Poralla, T.,

and Gerken, G., The asialoglycoprotein receptor mediates hepatic binding and uptake of natural hepatitis B virus particles derived from viraemic carriers. J Gen Virol 75 (Pt 11) (1994) 3021-3029.

[42] Zhang, X., Lin, S.M., Chen, T.Y., Liu, M., Ye, F., Chen, Y.R., Shi, L., He, Y.L., Wu, L.X., Zheng, S.Q., Zhao, Y.R., and Zhang, S.L., Asialoglycoprotein receptor interacts with the preS1 domain of hepatitis B virus in vivo and in vitro. Arch Virol 156 (2011) 637-645.

[43] Deng, Q., Zhai, J.W., Michel, M.L., Zhang, J., Qin, J., Kong, Y.Y., Zhang, X.X., Budkowska, A., Tiollais, P., Wang, Y., and Xie, Y.H., Identification and characterization of peptides that interact with hepatitis B virus via the putative receptor binding site. J Virol 81 (2007) 4244-4254.

[44] Urban, S., Breiner, K.M., Fehler, F., Klingmuller, U., and Schaller, H., Avian hepatitis B virus infection is initiated by the interaction of a distinct pre-S subdomain with the cellular receptor gp180. J Virol 72 (1998) 8089-8097.

[45] Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., Huang, Y., Qi, Y., Peng, B., Wang, H., Fu, L., Song, M., Chen, P., Gao, W., Ren, B., Sun, Y., Cai, T., Feng, X., Sui, J., and Li, W., Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. elife 1 (2012) e00049.

[46] Ueda, K., Start or end ?　One of the Biggest mysteries is finally solved? J Infect Dis Ther 1 (2013) e101.

[47] Ueda, K., One year passed since a bile acid transporter (sodium taurocholate cotransporting peptide [NTCP]) was nominated as a hepatitis B virus (HBV) entry receptor; has the NTCP been as a ral HBV receptor? J. Infect Dis Ther 1 (2013) e102.

[48] Neurath, A.R., Kent, S.B., Strick, N., and Parker, K., Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 46 (1986) 429-436.

[49] Pontisso, P., Ruvoletto, M.G., Gerlich, W.H., Heermann, K.H., Bardini, R., and Alberti, A., Identification of an attachment site for human

liver plasma membranes on hepatitis B virus particles. Virology 173 (1989) 522-530.

[50] Glebe, D., Urban, S., Knoop, E.V., Cag, N., Krass, P., Grun, S., Bulavaite, A., Sasnauskas, K., and Gerlich, W.H., Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 129 (2005) 234-245.

[52] Engelke, M., Mills, K., Seitz, S., Simon, P., Gripon, P., Schnolzer, M., and Urban, S., Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology 43 (2006) 750-760.

[51] Bremer, C.M., Sominskaya, I., Skrastina, D., Pumpens, P., El Wahed, A.A., Beutling, U., Frank, R., Fritz, H.J., Hunsmann, G., Gerlich, W.H., and Glebe, D., N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus. J Hepatol 55 (2011) 29-37.

[52] Engelke, M., Mills, K., Seitz, S., Simon, P., Gripon, P., Schnolzer, M., and Urban, S., Characterization of a hepatitis B and hepatitis delta virus

receptor binding site. Hepatology 43 (2006) 750-760.

[53] Blanchet, M., and Sureau, C., Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particle assembly and infectivity. J Virol 80 (2006) 11935-11945.

[54] Abou-Jaoude, G., and Sureau, C., Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange. J Virol 81 (2007) 13057-13066.

Figure legends

Fig. 1. Design of HBVpp packaging system. A. Construct of the retroviral genome. A MLV-based retroviral vector was constructed. As commonly used, this vector was two LTRs at the 5' and the 3' end. A Packaging signal (Ψ), a selection marker (Hyg^R), a CMV immediate early enhancer and promoter followed by a *GFP* gene are represented. B. An established packaging cell line is shown. This cells was generated in MLV gag-pol expressing GP2 (Clontech) cells, where the retroviral vector (see Fig. 1A) was integrated. As a result, the packaging cells express the Hyg^R and the *GFP* in addition to MLV gag-pol. C. A strategy of the generation of HBVpp. The established packaging cells could produce HBV membrane protein enveloped retroviral capsids, when HBV membrane proteins were successfully expressed.

Fig. 2. HBV membrane proteins and their expressing plasmid, pCEP4 LS-S. A. Three HBV membrane proteins are shown. The S region is shared by all HBV membrane proteins. A hexagon and a diamond represent an O-glycosylation and an N-glycosylation site, respectively. B. An expression map of HBV membrane

proteins. Arrows represent putative transcription start sites for each HBV membrane gene. C. HBV membrane protein expression was analyzed by immunoprecipitation with rabbit polyclonal anti-HBs antibodies followed by Western blot with a mouse monoclonal anti-HBs antibody. Input: lysate from the transfected cells. UB: unbound fractions with goat polyclonal anti-HBs antibodies (Austral Biologicals). B: bound fractions with the same antibodies. Arrowheads show authentic HBV membrane proteins.

Fig. 3. HBV membrane bound particles contains retroviral genomes inside. A. Culture medium of either HBV LS-S or VSV-G transfected packaging cells was immunoprecipitated with anti-S antibodies or anti-VSV-G antibodies. Putative RNA genomes were extracted from the immunoprecipitates and subjected to RT-PCR for the *EGFP* gene. Ab: antibody, IP: immunoprecipitation, RT: reverse transcription, +ve: positive. B. CsCl density gradient ultracentrifugaion profile, ELISA and RT-PCR of the each fraction. (Upper) Profiles of the density, ELISA for HBV membrane proteins (HBs and preS1). The left longitudinal axis shows the density of each fraction. ρ:

density, mg/ml. The right longitudinal axis shows OD_{450} values for HBs and preS1 measured with ELISA kits. (Lower) An agarose-gel electrophoresis of RT-PCR products of the *EGFP* gene as a target (about 320bp).

Fig. 4. Electronmicroscopy of intracellular sub-viral particles and secreted virus-like particles. a. Sub-viral particles accumulation were seen in the ER of LS-S expressing packaging cells. b. Secreted virus-like particles are shown.

Fig. 1


A
LTR
ψ
hyg
IE
p
GFP
LTR
B
LTR
ψ
hyg
E
p
GFP
LTR
gag
pol
gfp/GP2
C
LTR
ψ
hyg
E
p
GFP
LTR
gag
pol
+ HBV membrane proteins ⇒
HBVpp
GFP
GFP

Fig. 2


A
large S
preS1
preS2
S
middle S
preS2
S
small S
S
B
pCEP4 LS-S
CMV IEp
preS1
preS2
S
pA